Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 5-Day proton blast beat prostate cancer for good?

NCT ID NCT07699705

Disease control Sponsor: National Cancer Center, Korea Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study follows 50 men with localized prostate cancer who received a very short course of high-dose proton beam therapy (just 5 sessions). Researchers want to see how well this treatment controls cancer over the long term and what factors predict success or side effects. Participants will complete quality-of-life questionnaires and have regular checkups to track recurrence and survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ultrahypofractionated proton beam therapy
What this could lead to
If successful, this could help identify which patients benefit most from this precise, short-course radiation therapy, potentially improving treatment planning and reducing side effects.
What could go wrong
This is an observational study with only 50 participants, so results may not apply to all patients. Long-term outcomes are still unknown, and side effects from radiation remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Dec 2034

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed localized adenocarcinoma of the prostate. * No evidence of distant metastasis (M0). * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * Eligible to receive definitive image-guided ultrahypofractionated pencil beam scanning proton beam therapy according to the study protocol. * Ability to complete study questionnaires and comply with scheduled follow-up assessments. * Provision of written informed consent before study enrollment. Exclusion Criteria: * Residual or recurrent prostate cancer following prior radical prostatectomy. * Previous pelvic radiotherapy. * Evidence of distant metastatic disease. * Active malignancy within the previous 1 year, except adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or completely resected T1N0M0 malignancies. * Uncontrolled psychiatric illness, severe traumatic brain injury, chronic alcohol or substance dependence, or other medical conditions that, in the investigator's judgment, would preclude safe participation or adequate follow-up. * Inability or unwillingness to provide written informed consent or comply with study procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Localized prostate adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate neoplasm

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Cancer Center, Korea

    RECRUITING

    Goyang-si, Gyeonggi-do, 10408, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.